Spondyloarthritis & psoriatic arthritis
Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis
Authors' conclusion
In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r-axSpA. Regardless of treatment in r-axSpA, having a history of uveitis appeared to predispose patients for future uveitis events.
Study context
- Population
- Patients with PsA, r-axSpA or nr-axSpA in five clinical trials (PsA 2, r-axSpA 2, nr-axSpA 1)5 clinical trials
- Comparison
- Upadacitinib 15 mg vs placebo
- Outcome
- Treatment-emergent EMMs (uveitis, IBD, psoriasis), exposure-adjusted event rates (E/100 PY)
Methodological detailsexposure-adjusted event rates (E/100 PY), data cutoff August 15, 2022
- Exposure-adjusted event rates (E/100 PY)
- Data cutoff August 15, 2022
Pooled result
As reported in the abstract
Uveitis in r-axSpA (E/100 PY)
Further pooled results
E/100 PY
| Outcome | Upadacitinib 15 mg | Placebo |
|---|---|---|
| Uveitis in r-axSpA, no history of uveitis (E/100 PY) | 0.6 | 1.2 |
| Uveitis in r-axSpA, history of uveitis (E/100 PY) | 2.1 | 6.2 |
| Uveitis in nr-axSpA (E/100 PY) | 0.9 | 2.1 |
Uveitis and inflammatory bowel disease (IBD) in PsA
- Low regardless of treatment or prior EMM history; rates similar with upadacitinib 15 mg and adalimumab
IBD and psoriasis in r-axSpA and nr-axSpA
- Low regardless of treatment or history in r-axSpA; low or absent in nr-axSpA
No history of extramusculoskeletal manifestations (EMMs) at baseline
- Most patients
- 87.1%-99.3%
Original publication
Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →